1862-88-0

Usage

Uses

Used in Pharmaceutical Industry:
N-Methylsalicylamide is used as an intermediate in the synthesis of various drugs for its anti-inflammatory and analgesic properties. It is particularly beneficial in the development of medications targeting conditions like arthritis, where its ability to inhibit prostaglandin production can help manage inflammation and pain.
Used in Therapeutic Applications:
N-Methylsalicylamide is used as a potential therapeutic agent for conditions such as arthritis, where its capacity to reduce inflammation and alleviate pain is valuable. Research into its effects on prostaglandin production suggests that it could offer relief in managing the symptoms of such conditions.
Used in Industrial Applications:
Beyond its pharmaceutical uses, N-Methylsalicylamide is also utilized in industrial settings. It is employed in the synthesis of other chemicals, contributing to the creation of a variety of products. Additionally, it has been investigated for its potential as a corrosion inhibitor, highlighting its versatility in different sectors.

InChI:InChI=1/C8H9NO2/c1-9-8(11)6-4-2-3-5-7(6)10/h2-5,10H,1H3,(H,9,11)

Upstream product

• 118-55-8 phenyl Salicylate 
• 74-89-5 methylamine 
• 624-83-9 methyl isocyanate 
• 108-95-2 phenol 
• 118904-09-9 benzoyl-(2-benzoyloxy-benzoyl)-methyl-amine 
• 1196-29-8 2-hydroxyacetophenoneoxime 
• 69-72-7 salicylic acid 
• 80-43-3 bis(1-methyl-1-phenylethyl)peroxide 
• 65-45-2 salicylamide 
• 1778-08-1 2-hydroxy-N,N-dimethylbenzamide 
• 61141-14-8 anionic phenyl salicylate 
• 3400-35-9 2-methoxy-N-methylbenzamide 
• 1672-01-1 3-methyl-benzo<1,3>oxazine-2,4-dione 
• 73388-46-2 2-(methylcarbamoyl)phenyl acetate 

Downstream Products

• 118904-10-2 2-benzoyloxy-benzoic acid methylamide 
• 3400-35-9 2-methoxy-N-methylbenzamide 
• 100610-83-1 2-α-L-arabinopyranosyloxy-benzoic acid methylamide 
• 110423-86-4 2-(tri-O-acetyl-β-D-xylopyranosyloxy)-benzoic acid methylamide 
• 114329-76-9 2-(tetra-O-acetyl-β-D-glucopyranosyloxy)-benzoic acid methylamide 
• 1672-01-1 3-methyl-benzo<1,3>oxazine-2,4-dione 
• 143000-15-1 3-Methyl-2-oxo-2-phenyl-2,3-dihydro-2λ⁵-benzo[e][1,3,2]oxazaphosphinin-4-one 
• 119123-56-7 (E)-2-(crotyloxy)-N-methylbenzamide 
• 81109-77-5 1'-benzyl-3-methylspiro<1,3-benzoxazine-2,4'-piperidin>-4(3H)-one 
• 139553-96-1 10-Methyl-2-phenyl-1H-2,3,9,10-tetrahydropyrrolo<3,4-b><1,4>benzoxazepine-1,3,9-trione 
• 119123-54-5 2-(allyloxy)-N-methylbenzamide 
• 151414-63-0 2-trimethylsiloxy-N-methyl benzamide 
• 54808-59-2 5-bromo-N-methylsalicylamide 
• 98554-60-0 3,5-diiodo-N-methylsalicylamide 

Relevant academic research and scientific papers

Asymmetric Hydrogenation of Cationic Intermediates for the Synthesis of Chiral N,O-Acetals

For over half a century, transition-metal-catalyzed homogeneous hydrogenation has been mainly focused on neutral and readily prepared unsaturated substrates. Although the addition of molecular hydrogen to C=C, C=N, and C=O bonds represents a well-studied paradigm, the asymmetric hydrogenation of cationic species remains an underdeveloped area. In this study, we were seeking a breakthrough in asymmetric hydrogenation, with cationic intermediates as targets, and thereby anticipating applying this powerful tool to the construction of challenging chiral molecules. Under acidic conditions, both N- or O-acetylsalicylamides underwent cyclization to generate cationic intermediates, which were subsequently reduced by an iridium or rhodium hydride complex. The resulting N,O-acetals were synthesized with remarkably high enantioselectivity. This catalytic strategy exhibited high efficiency (turnover number of up to 4400) and high chemoselectivity. Mechanistic studies supported the hypothesis that a cationic intermediate was formed in situ and hydrogenated afterwards. A catalytic cycle has been proposed with hydride transfer from the iridium complex to the cationic sp2 carbon atom being the rate-determining step. A steric map of the catalyst has been created to illustrate the chiral environment, and a quantitative structure–selectivity relationship analysis showed how enantiomeric induction was achieved in this chemical transformation.

Discovery of 5-bromo-4-phenoxy-N-phenylpyrimidin-2-amine derivatives as novel ULK1 inhibitors that block autophagy and induce apoptosis in non-small cell lung cancer

UNC51-like kinase1 (ULK1) recruits its binding partners and initiates the autophagy process in cancer. ULK1 is significantly overexpressed in Non-small cell lung cancer (NSCLC) and negatively correlated with clinical prognosis in NSCLC patients. Based upo

NOVEL ULK1 INHIBITORS AND METHODS USING SAME

In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.

Copper-catalyzed N-methylation of amides and O-methylation of carboxylic acids by using peroxides as the methylating reagents

The copper-catalyzed N-methylation of amides and O-methylation of carboxylic acids by using peroxides as the methylating reagent are described. Various amides and carboxylic acids were methylated affording N-substituted amides and esters. Tentative mechanistic studies suggest that this reaction is likely to involve a radical process.

Evaluation of 1-arylpiperazine derivative of hydroxybenzamides as 5-HT 1A and 5-HT7 serotonin receptor ligands: An experimental and molecular modeling approach

The synthesis and evaluation as 5-HT1A and 5-HT7 serotonin receptor ligands of the two sets of O-substituted hydroxybenzamides, structurally related to 2-{3-[4-(2-methoxyphenyl)piperazin-1-yl]propoxy} benzamide (1), (Ki 5-

NOVEL TRICYCLIC SPIRODERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

The invention provides compounds of formula (I) wherein m, R1, n, R2, q, X, Y, Z, R3, R4, R5, R6, R7, R8, t and R9 are as defined in the specification, proc

NOVEL TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES

The invention provides compounds of formula (I) wherein m, R1, n, R2, q, X, Y, Z, R3, R4, R5, R6, R7, R8, t and R9 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

A short and efficient preparation of methyl-[1,2,4]oxadiazolium derivatives with plant-inducing activity

A short and efficient preparation of methyl-[1,2,4]oxadiazolium derivatives with plant-inducing activity is discussed. A concise and efficient synthetic method leading to structurally diverse array of oxadiazolium derivatives, starting from halogenated phenols is also developed. The starting point of the synthesis is the Lewis acid mediated addition of isocyanates to phenols. The strategy also involves a new and rapid access to all meta-halogenated salicylic acids, compounds of high synthetic value.

Indole carboxylic acids as thyroid receptor ligands

A compound of the formula wherein W, R1, R2, R3, R4, R5, R6, R7, R8 and R13 are as defined herein, useful in the treatment of obesity, overweight condition, hyperlipidemia, glaucoma, cardiac arrhythmias, skin disorders, thyroid disease, hypothyroidism, th

11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA

Compounds having Formula (I), including pharmaceutically acceptable salts, hydrates and solvates thereof, are selective inhibitors of the 11β-HSD1 enzyme. The compounds are useful for the treatment of diabetes, such as noninsulin-dependent diabetes (NIDDM), hyperglycemia, obesity, insulin resistance, dylsipidemia, hyperlipidemia, hypertension, Syndrome X, and other symptoms associated with NIDDM.